Clinical Trials Directory

Trials / Unknown

UnknownNCT04930510

Coronary Artery Disease in Elderly People Referred for TAVI

IncIncidence and Prognosis of Coronary Artery Disease in Elderly People Over 80 Years Referred for TAVI

Status
Unknown
Phase
Study type
Observational
Enrollment
170 (estimated)
Sponsor
University Hospital, Montpellier · Academic / Other
Sex
All
Age
80 Years
Healthy volunteers
Not accepted

Summary

The investigators prognostic impact of coronary artery disease (CAD) and of percutaneous coronary intervention (PCI) in patients with indication of TAVI is controversial, particularly in elderly population where CAD and aortic stenosis (AS) are frequent and commonly coexisted. (1-2) The primary end point of this prospective study is to compare major cardiovascular event at one year of follow up in patients over 80 years with severe aortic stenosis who referred for TAVI with or without associated CAD. The investigators will also assess (secondary endpoint) the impact of PCI on symptoms, major events and quality of life using geriatric parameters. The study will be conducted in the University hospital of Montpellier between November 2020 and November 2022

Detailed description

Patients will be prospectively included in the study when aged of 80 years old or over and referred for TAVI at the university hospital of Montpellier. Two groups of patients will be considered after coronary angiography which is systematic before TAVI Group 1: patients with significant \> 50 % narrowing coronary stenosis ( revascularization by PCI / no revascularization) Group 2: No coronary lesion Considering an end point at 1 year and a precision wished to i ± 6 percent with an alpha risk of 5 %, it's proposed , by the formula p= \[(1.96)2 x \[p(1-p)\] / i2 \], a number of 170 subjects needed to highlight a incidence of major cardio-vascular event of 20 percent in the studied population. Data collection by informatic files will include : * Cardio vascular risk factor and medical history with evaluation of Charlston score * Previous drug therapy * Lifestyle : living alone or not, nursing home, ; home help * Symptoms (angina (CSS classification) ; dyspnea (NHYA classification)) * Renal function (DFG) at admission * Results of coronary angiography (number of lesions, proximal or non proximal, location of coronary stenosis) * Geriatric assessment : autonomy, disability in daily living, weigh, BMI, falls, cognitive functions tests, assessment of the mood state by GDS * Results of TAVI (success and complications of the procedure according to VARC2 criteria) * Results of coronary revascularization if performed * Length of hospitalisation for TAVI (days), length of stay in ICU (Intensive Care Unit) if necessary * Events during the hospitalisation for TAVI (VARC and BARC criterias) Follow up at 6 month (middle analysis) and at one year (primary end point) by phone conversation with the patient for assessment of : * Major cardio-vascular events * Hospitalisation occurred * Short geriatric evaluation including : * cognition by Ottawa3DY * autonomy by ADL * polypharmacy * number of fall in the past 6 month * last weight * quality of life (Fried criterias) * mood state by GDS If neurocognitive disorders are known or discovers, data patient's validity will be check by calling his caregiver and/or his general practitioner (if caregiver not available). Analysis associated of the computerized patient record.

Conditions

Timeline

Start date
2020-11-01
Primary completion
2022-11-01
Completion
2023-11-01
First posted
2021-06-18
Last updated
2021-06-18

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT04930510. Inclusion in this directory is not an endorsement.